Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LMB-100 + SVP-rapa |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LMB-100 | RG7787|RO-6927005|RO6927005|LMB100 | LMB-100 is an immunotoxin that targets mesothelin, potentially resulting in antitumor activity (PMID: 27863199, PMID: 32611684). | ||
| SVP-rapa | SEL-110|SEL110 | SVP-rapa is a drug comprised of synthetic vaccine particles that contain rapamycin, which blocks antibodies from forming upon treatment with immunogenic-type therapies (Cancer Res 2017;77(13 Suppl):Abstract nr 72). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03436732 | Phase I | LMB-100 + SVP-rapa | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | Terminated | USA | 0 |